HUTCHMED China Ltd Total Liabilities
HUTCHMED China Ltd total liabilities. Based on the latest financial reports, HUTCHMED China Ltd (HCM) has total liabilities worth GBX501.83 Million GBX (≈ $61.06K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of HUTCHMED China Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HUTCHMED China Ltd (2005–2025)
Total liabilities of HUTCHMED China Ltd from 2005 to 2025. This chart illustrates how HUTCHMED China Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of HUTCHMED China Ltd to see how much of total assets are deployed in long-term investments.
HUTCHMED China Ltd Competitors by Total Liabilities
The table below lists competitors of HUTCHMED China Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reitmans Canada Ltd
V:RET
|
Canada | CA$266.94 Million |
|
Cobalt Blue Holdings Ltd
AU:COB
|
Australia | AU$3.69 Million |
|
AJ Advance Technology Public Company Limited
BK:AJA
|
Thailand | ฿117.86 Million |
|
Kingsmen Resources Ltd
V:KNG
|
Canada | CA$50.53K |
|
Boat Rocker Media Inc
TO:BRMI
|
Canada | CA$173.23 Million |
|
ELUON Corporation
KQ:065440
|
Korea | ₩26.80 Billion |
|
AIRA Factoring Public Company Limited
BK:AF
|
Thailand | ฿1.92 Billion |
|
Ogunsen AB Series B
ST:OGUN-B
|
Sweden | Skr84.80 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down HUTCHMED China Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is HUTCHMED China Ltd's balance sheet.
Liquidity & Leverage Metrics
HUTCHMED China Ltd Total Liabilities Ratios Explained
HUTCHMED China Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HUTCHMED China Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HUTCHMED China Ltd (2005–2025)
The table below shows the annual total liabilities of HUTCHMED China Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX501.15 Million ≈ $60.98K |
-0.24% |
| 2024-12-31 | GBX502.34 Million ≈ $61.12K |
-6.35% |
| 2023-12-31 | GBX536.39 Million ≈ $65.26K |
+36.63% |
| 2022-12-31 | GBX392.57 Million ≈ $47.77K |
+17.84% |
| 2021-12-31 | GBX333.15 Million ≈ $40.53K |
+62.38% |
| 2020-12-31 | GBX205.17 Million ≈ $24.96K |
+34.79% |
| 2019-12-31 | GBX152.22 Million ≈ $18.52K |
+26.99% |
| 2018-12-31 | GBX119.86 Million ≈ $14.58K |
+6.11% |
| 2017-12-31 | GBX112.97 Million ≈ $13.74K |
-18.36% |
| 2016-12-31 | GBX138.38 Million ≈ $16.84K |
+8.55% |
| 2015-12-31 | GBX127.48 Million ≈ $15.51K |
+28.69% |
| 2014-12-31 | GBX99.06 Million ≈ $12.05K |
+22.55% |
| 2013-12-31 | GBX80.83 Million ≈ $9.83K |
-35.76% |
| 2012-12-31 | GBX125.82 Million ≈ $15.31K |
+7.13% |
| 2011-12-31 | GBX117.44 Million ≈ $14.29K |
+28.89% |
| 2010-12-31 | GBX91.12 Million ≈ $11.09K |
+73.71% |
| 2009-12-31 | GBX52.45 Million ≈ $6.38K |
+56.43% |
| 2008-12-31 | GBX33.53 Million ≈ $4.08K |
+11.93% |
| 2007-12-31 | GBX29.96 Million ≈ $3.64K |
+29.89% |
| 2006-12-31 | GBX23.06 Million ≈ $2.81K |
-74.63% |
| 2005-12-31 | GBX90.89 Million ≈ $11.06K |
-- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more